U.S. markets open in 4 hours 56 minutes

Viveve Medical, Inc. (VIVE)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
2.9500+0.0200 (+0.68%)
At close: 4:00PM EDT
3.0000 +0.05 (1.69%)
Pre-Market: 04:05AM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Inside Bar (Bearish)

Inside Bar (Bearish)

Previous Close2.9300
Bid2.9000 x 800
Ask3.0300 x 1800
Day's Range2.8924 - 3.0300
52 Week Range2.4000 - 14.4000
Avg. Volume330,241
Market Cap31.246M
Beta (5Y Monthly)0.68
PE Ratio (TTM)N/A
EPS (TTM)-7.3160
Earnings DateAug 11, 2021 - Aug 16, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est9.63
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more

    Viveve Announces Issuance of New Device and Methods Patent in U.S.

    ENGLEWOOD, CO / ACCESSWIRE / June 10, 2021 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, today announced that the United States Patent and Trademark Office (USPTO) recently issued U.


    Viveve Announces Adjournment of Annual Meeting

    * Meeting scheduled to reconvene June 23, 2021 at 12:00 PM Eastern Time * Company encourages stockholders to cast their votesENGLEWOOD, CO / ACCESSWIRE / June 2, 2021 / Viveve Medical, Inc. (NASDAQ:VIVE), a medical technology company focused on women's intimate health, today announced that it has adjourned its 2021 Annual Meeting of Stockholders for a second time due to a lack of quorum.


    Viveve Reports First Quarter 2021 Financial Results and Provides Corporate Update

    Pivotal SUI PURSUIT trial enrollment underway and acceleratingTotal revenue of $1.5M for Q1 including sale of 2,450 consumable treatment tips Strengthened patent portfolio in key Asia Pacific marketsENGLEWOOD, CO / ACCESSWIRE / May 13, 2021 / Viveve Medical, Inc.